anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

210,241-210,300 of 319,975

filter-aware
17
The chart shows FFIC consistently outperforming the industry in net charge-offs.Flushing Financial | Results Presentation Deck | 37 slides · Flushing Financial Corporation
Conference presentation Investor relations Beat · Satisfaction1 hit
18
Includes peer comparison data for FFIC against a specific peer group.Flushing Financial | Results Presentation Deck | 37 slides · Flushing Financial Corporation
Conference presentation Investor relations Beat · Satisfaction1 hit
19
The slide displays two bar charts with overlaid line graphs representing financial ratios.Flushing Financial | Results Presentation Deck | 37 slides · Flushing Financial Corporation
Conference presentation Investor relations Beat · Satisfaction1 hit
20
Flushing Financial | Results Presentation Deck | 37 slidesFlushing Financial | Results Presentation Deck | 37 slides · Flushing Financial Corporation
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
21
Flushing Financial | Results Presentation Deck | 37 slidesFlushing Financial | Results Presentation Deck | 37 slides · Flushing Financial Corporation
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
22
Flushing Financial | Results Presentation Deck | 37 slidesFlushing Financial | Results Presentation Deck | 37 slides · Flushing Financial Corporation
Conference presentation Investor relations 1 hit
23
The table includes a footnote regarding the reconciliation of GAAP and Core earnings.Flushing Financial | Results Presentation Deck | 37 slides · Flushing Financial Corporation
Conference presentation Investor relations 1 hit
24
The slide uses bar charts to visualize CAGR and absolute growth across multiple financial indicators.Flushing Financial | Results Presentation Deck | 37 slides · Flushing Financial Corporation
Conference presentation Investor relations 1 hit
25
Comparison of two distinct portfolio segments with donut charts and bulleted performance metrics.Flushing Financial | Results Presentation Deck | 37 slides · Flushing Financial Corporation
Conference presentation Investor relations 1 hit
26
The chart highlights a $704MM Real Estate Collateral segment. The footer notes an average loan size of $1.2MM.Flushing Financial | Results Presentation Deck | 37 slides · Flushing Financial Corporation
Conference presentation Investor relations 1 hit
27
This is a standard financial disclosure slide often found in investor presentations to justify the use of non-GAAP metrics.Flushing Financial | Results Presentation Deck | 37 slides · Flushing Financial Corporation
Conference presentation Investor relations 1 hit
28
Includes footnotes regarding rounding and annualized ratios.Flushing Financial | Results Presentation Deck | 37 slides · Flushing Financial Corporation
Conference presentation Investor relations 1 hit
29
Includes a footnote defining the Efficiency Ratio calculation.Flushing Financial | Results Presentation Deck | 37 slides · Flushing Financial Corporation
Conference presentation Investor relations 1 hit
30
Includes footnotes regarding exclusions for purchase accounting average balances.Flushing Financial | Results Presentation Deck | 37 slides · Flushing Financial Corporation
Conference presentation Investor relations 1 hit
31
Flushing Financial | Results Presentation Deck | 37 slidesFlushing Financial | Results Presentation Deck | 37 slides · Flushing Financial Corporation
Conference presentation Investor relations 1 hit
32
Includes adjustments for credit losses, fair value adjustments, asset sales, and other non-recurring items.Flushing Financial | Results Presentation Deck | 37 slides · Flushing Financial Corporation
Conference presentation Investor relations 1 hit
33
The table provides a detailed breakdown of adjustments for the years 2017-2022.Flushing Financial | Results Presentation Deck | 37 slides · Flushing Financial Corporation
Conference presentation Investor relations 1 hit
34
The table includes adjustments for fair value hedges, purchase accounting, and tax equivalents.Flushing Financial | Results Presentation Deck | 37 slides · Flushing Financial Corporation
Conference presentation Investor relations 1 hit
35
Data is in thousands of dollars.Flushing Financial | Results Presentation Deck | 37 slides · Flushing Financial Corporation
Conference presentation Investor relations 1 hit
36
Flushing Financial | Results Presentation Deck | 37 slidesFlushing Financial | Results Presentation Deck | 37 slides · Flushing Financial Corporation
Conference presentation Investor relations 1 hit
37
Flushing Financial | Results Presentation Deck | 37 slidesFlushing Financial | Results Presentation Deck | 37 slides · Flushing Financial Corporation
Conference presentation Investor relations 1 hit
01
Slide 1
Includes company logo and tagline.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit
02
Genelux | Investor Presentation Deck | 38 slidesGenelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit
03
Genelux | Investor Presentation Deck | 38 slidesGenelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit
04
Genelux | Investor Presentation Deck | 38 slidesGenelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Problem1 hit
05
The slide uses a Gantt-style visualization to map drug development progress against clinical phases.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Problem1 hit
06
Uses a process diagram to illustrate the transition from cold to hot tumor states.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Problem1 hit
07
The central diagram illustrates the biological mechanism of action, contrasting the absence vs. presence of effector T cells.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution1 hit
08
The slide uses a timeline to establish market validation through historical M&A and financing events.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution1 hit
09
The slide uses a list-based comparison and a logo-grid to frame the competitive landscape.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Solution1 hit
10
The slide uses a pyramid diagram to represent the evolution of oncolytic virus technology, with Genelux's platform at the top.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit
11
The slide uses a document-style container for patient background and icon-based lists for clinical outcomes.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit
12
The slide uses a process-flow layout to show the trial design and its downstream impact (publications and Phase 3).Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
13
Data table presents ORR, Duration of Response, CA-125 response, PFS, and OS across patient subgroups.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
14
Includes a spider plot (tumor shrinkage over time) and a waterfall plot (duration of response).Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
15
The slide uses a series of bar charts to compare PFS across multiple treatment regimens for three specific patients (15B-01, 15B-15, 15B-17).Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
16
Kaplan-Meier survival curve showing patient outcomes.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit
17
The slide uses a cross-trial comparison to highlight the efficacy of Olvi-Vec in heavily pre-treated patients compared to other standard regimens.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit
18
The slide outlines a randomized, open-label trial comparing Olvi-Vec + Platinum-doublet + Bevacizumab against a standard comparator arm.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
19
Includes Kaplan-Meier survival curves and dose escalation scatter plots for two distinct patient groups.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
20
Includes two specific patient case studies with longitudinal data and RECIST response metrics.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
21
Includes a bio for Benny Li, PhD, CEO of Newsoara.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit
22
The table outlines a strategic partnership involving funding and regional commercialization rights.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit
23
The slide highlights a combination therapy approach using two distinct technologies with separate clinical trial data.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit
24
Includes a map of the US as a background element, likely to denote the geographic scope of the market sizing.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Market Size1 hit
25
The slide highlights physical assets and operational capacity.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Market Size1 hit
26
The slide uses a hub-and-spoke style layout to show the four pillars supporting the central launch strategy.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit
27
The slide categorizes the platform's capabilities into therapeutic genes, immune modularity, and therapeutic antibodies.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit
28
Genelux | Investor Presentation Deck | 38 slidesGenelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit
29
Genelux | Investor Presentation Deck | 38 slidesGenelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Team1 hit
30
The slide uses a split layout: a list for past achievements and an arrow-based timeline for future goals.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Team1 hit
31
Includes footnotes regarding reconciliation of cap table and specific financing commitments.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit
32
Genelux | Investor Presentation Deck | 38 slidesGenelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit
33
Genelux | Investor Presentation Deck | 38 slidesGenelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit
34
The slide highlights the credibility of the advisory board through their affiliations with major cancer research organizations and clinical trial experience.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit
35
Includes microscopic imagery of patient samples (Pt.#15A-01 and Pt.#15A-11) showing longitudinal progression of treatment.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit
36
The slide uses a before-and-after comparison of histology images and corresponding infiltration histograms to demonstrate drug efficacy.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit
37
Includes a clinical case study (Pt #15A-05) with ELISPOT data and longitudinal tumor lesion size tracking.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit
38
The slide uses clinical study data (VIRO-15, NCT01443260) to support its claims about immune modulation.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations 1 hit
01
Slide 1
Goldman Sachs | Results Presentation Deck | 15 slidesGoldman Sachs | Results Presentation Deck | 15 slides · Goldman Sachs
Conference presentation Investor relations Beat · What Is1 hit